Inhibition of the ROS-EGFR Pathway Mediates the Protective Action of Nox1/4 Inhibitor GKT137831 against Hypertensive Cardiac Hypertrophy via Suppressing Cardiac Inflammation and Activation of Akt and ERK1/2

Table 2

Effect of selective epidermal growth factor receptor (EGFR) inhibitor AG1478 on echocardiographic and hemodynamic parameters in spontaneously hypertensive rats.

	Control	SHR	SHR+AG1478
LVAWd (mm)		^#
LVAWs (mm)		^#
LVPWd (mm)		^#
LVPWs (mm)		^#
LVIDd (mm)			6.54 ± 0.79
LVIDs (mm)			4.33 ± 0.65
Fractional shortening (%)			34.68 ± 6.78
Ejection fraction (%)			62.75 ± 8.97
AoSP (mmHg)		^#	177 ± 8.9
AoDP (mmHg)		^#	103 ± 5.6
Heart rate (beats/min)			379.7 ± 30.7
max (mmHg/s)		^#
min (mmHg/s)		^#

SHR represents spontaneously hypertensive rats. LVAWd: left ventricular anterior wall thickness during diastole; LVAWs: left ventricular anterior wall thickness during systole; LVPWd: left ventricular posterior wall thickness during diastole; LVPWs: left ventricular posterior wall thickness during systole; LVIDd: LV internal diameter during diastole; LVIDs: LV internal diameter during systole; AoSP: aortic systolic pressure; AoDP: aortic diastolic pressure; max: the maximal rate of left ventricular pressure increase; min: the maximal rate of left ventricular pressure decrease. Data are expressed as , . The analytical tests were implemented using one-way ANOVA followed by the post hoc test. ^# vs. the control group; vs. the SHR group.